by Sean Hughes | May 11, 2026 | EPO
Sequence Identity Claims After T 0137/24 The recent Board of Appeal decision in T 0137/24 provides useful guidance on how sequence identity claims are assessed under the EPC, particularly in relation to added matter and sufficiency. Biotech sequence-related claims are...
by Alyson Lam | Apr 29, 2026 | EPO
Summary of T 439/22 This decision represents a further development of the earlier T 439/22 proceedings, which led to the G1/24 referral to the EPO’s Enlarged Board of Appeal (EBA). The decision of the EBA was reported in our previous article. To recap, granted claim 1...
by Sean Hutchinson | Apr 7, 2026 | US & International
Background: PGR and IPR Patent offices around the world strive to grant valid patents, but sometimes cases slip through the net and proceed to grant when they shouldn’t have. For this reason, many patent offices provide mechanisms for third parties to challenge their...
by David Eyre | Mar 4, 2026 | US & International
Background REGENXBIO and the Trustees of the University of Pennsylvania sued Sarepta for infringing multiple claims of U.S. Patent No. 10,526,617, which is directed to cultured host cells containing a recombinant nucleic acid molecule encoding an AAV capsid sequence...
by David Eyre | Feb 18, 2026 | US & International
This case is important because it allows the Supreme Court to define the point of balance between enforcement of patent rights for medical uses and the competition in the market place for generic pharmaceuticals. Consequently, the ruling of the Supreme Court will have...
Recent Comments